Fuzeon Needle-Free Delivery System To Be Resubmitted To FDA In Second Half 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Growth for Roche/Trimeris' HIV fusion inhibitor is expected to be driven by the new system, which is currently "approvable" at FDA, and updated HHS treatment guidelines.
You may also be interested in...
Trimeris Shifts Focus Away From Fuzeon, Toward Pipeline Diversity
Restructuring plan, expected to wrap up by early 2007, will transfer some Fuzeon marketing responsibilities to Roche.
Trimeris Shifts Focus Away From Fuzeon, Toward Pipeline Diversity
Restructuring plan, expected to wrap up by early 2007, will transfer some Fuzeon marketing responsibilities to Roche.
FDA Seeks More Information On Use of Fuzeon With Needle-Free Injector
Roche/Trimeris received an “approvable” letter from FDA for the HIV therapy Fuzeon administered with a needle-free Biojector device.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: